Sanofi has announced that it will lower the list price of its insulin drug, Lantus, by 78 percent and will set a $35 cap on out-of-pocket costs for all patients.
The price change and cap will go into effect starting January 1, 2024. They follow a series of moves made last year to lower the price of diabetes medicine, including the launch of an unbranded version of Lantus and a $35 cap for uninsured patients.
Yet, Olivier Bogillot, head of U.S. general medicines at Sanofi, said "the health system was unable to take advantage of it due to its inherent structural challenges."
“Sanofi believes that no one should struggle to pay for their insulin and we are proud of our continued actions to improve access and affordability for millions of patients for many years," he said. "Our decision to cut the list price of our lead insulin needs to be coupled with broader change to the overall system to actually drive savings for patients at the pharmacy counter.”
Sanofi will also cut the price of short-acting Apidra by 70 percent.
Paul Dergarabedian, Senior Media Analyst at Comscore shares the ups and downs that hit box offices in 2024, and how "Glicked" helped end the year back on top.
Founder & CEO of Sustainable Skylines, Jacob Stonecipher, joins Cheddar to discuss how is company is bringing intelligent drone-based advertising to our coasts.
With a ban on the horizon, Frank McCourt, Founder of Project Liberty, wants to purchase TikTok and put people in control of their digital identities and data.
Angie Hicks, Co-Founder at Angi, gives tips to avoid blowing your fuse while decking the halls, plus, winterization preparations you may have forgotten!
Matt Durot, Senior Reporter at Forbes, joins Cheddar to unpack all things Elon Musk including his soaring wealth, relationship to Trump and if he has a will.
David McKillips, President and CEO of CEC Entertainment, discusses the ongoing Chuck E. Cheese brand refresh, new locations, updated play spaces and more.
